<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37949376</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7492</ISSN><JournalIssue CitedMedium="Internet"><Volume>339</Volume><PubDate><Year>2024</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>Virus research</Title><ISOAbbreviation>Virus Res</ISOAbbreviation></Journal><ArticleTitle>Effects of glycine 64 substitutions in RNA-dependent RNA polymerase on ribavirin sensitivity and pathogenicity of coxsackievirus A6.</ArticleTitle><Pagination><StartPage>199268</StartPage><MedlinePgn>199268</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">199268</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virusres.2023.199268</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-1702(23)00230-7</ELocationID><Abstract><AbstractText>Hand, foot, and mouth disease (HFMD) caused by a group of enteroviruses is a global public health problem. In recent years, coxsackievirus A6 (CVA6) has emerged as an important HFMD agent. Previous studies have shown that mutations of glycine 64 in RNA-dependent RNA polymerase (3D polymerase), which is central to viral replication, cause phenotypic changes such as ribavirin resistance, increased replication fidelity, and virulence attenuation in poliovirus and enterovirus A71. In this study, we constructed CVA6 mutants with G64R, G64S, and G64T substitutions by site-directed mutagenesis in full-length cDNA of an infectious CVA6 strain cloned in pcDNA3.1. Viral RNA was obtained by in vitro transcription, and the rescued virus strains were propagated in RD cells. Sequencing after six passages revealed that G64S and G64T mutations were stably inherited, whereas G64R was genetically unstable and reversed to the wild type. Comparison of the biological characteristics of the wild-type and mutant CVA6 strains in an in vivo model (one-day-old ICR mice) revealed that the pathogenicity of CVA6-G64S and CVA6-G64T was significantly reduced compared to wild-type CVA6. In vitro experiments indicated the mutant CVA6-G64S and CVA6-G64T strains had increased resistance to 0.8 mM ribavirin and a decreased replication rate in the presence of 0.8 mM guanidine hydrochloride. Our results show that mutation of residue 64 reduces CVA6 susceptibility to ribavirin and increases CVA6 susceptibility to guanidine hydrochloride, together with increased replication fidelity and attenuated viral pathogenicity, thus laying a foundation for the development of safe and effective live attenuated CVA6 vaccine.</AbstractText><CopyrightInformation>Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Weifang Medical University, Weifang 261053, China; National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China; WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China; WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Jinbo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China; WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Congcong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Weifang Medical University, Weifang 261053, China; National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China; WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoliang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China; WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China; Department of Public Health, Shandong First Medical University &amp; Shandong Academy of Medical Sciences, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jichen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China; WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China; WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Huanhuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China; WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China; WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Shuangli</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China; WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhijun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, Weifang Medical University, Weifang 261053, China. Electronic address: zhijun.liu@wfmc.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID). National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China; WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No.155 Changbai Road, Beijing 102206, China. Electronic address: yongzhang75@sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virus Res</MedlineTA><NlmUniqueID>8410979</NlmUniqueID><ISSNLinking>0168-1702</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>JU58VJ6Y3B</RegistryNumber><NameOfSubstance UI="D019791">Guanidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="D012324">RNA-Dependent RNA Polymerase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086902">Viral Replicase Complex Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019791" MajorTopicYN="N">Guanidine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012324" MajorTopicYN="Y">RNA-Dependent RNA Polymerase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086902" MajorTopicYN="Y">Viral Replicase Complex Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3D polymerase</Keyword><Keyword MajorTopicYN="N">Attenuated virulence</Keyword><Keyword MajorTopicYN="N">Coxsackievirus A6</Keyword><Keyword MajorTopicYN="N">Glycine 64</Keyword><Keyword MajorTopicYN="N">Replication fidelity</Keyword><Keyword MajorTopicYN="N">Ribavirin insensitivity</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>11</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>10</Day><Hour>19</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37949376</ArticleId><ArticleId IdType="pmc">PMC10685073</ArticleId><ArticleId IdType="doi">10.1016/j.virusres.2023.199268</ArticleId><ArticleId IdType="pii">S0168-1702(23)00230-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agol V.I. Vaccine-derived polioviruses. Biologicals. 2006;34(2):103–108.</Citation><ArticleIdList><ArticleId IdType="pubmed">16650771</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomqvist S., Klemola P., Kaijalainen S., Paananen A., Simonen M.L., Vuorinen T., Roivainen M. Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland. J. Clin. Virol. 2010;48(1):49–54.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189452</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns C.C., Diop O.M., Sutter R.W., Kew O.M. Vaccine-derived polioviruses. J. Infect. Dis. 2014;210 Suppl 1:S283–S293.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>Campagnola G., Gong P., Peersen O.B. High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. Antiviral Res. 2011;91(3):241–251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3159743</ArticleId><ArticleId IdType="pubmed">21722674</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Zhou Y., Chen Y., Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884–i890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6129281</ArticleId><ArticleId IdType="pubmed">30423086</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T.C., Weng K.F., Chang S.C., Lin J.Y., Huang P.N., Shih S.R. Development of antiviral agents for enteroviruses. J. Antimicrob. Chemother. 2008;62(6):1169–1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">18931391</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochi S.L., Pallansch M.A. The long and winding road to eradicate vaccine-related polioviruses. J. Infect. Dis. 2021;223(1):7–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10546420</ArticleId><ArticleId IdType="pubmed">32621744</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras A.M., Hiasa Y., He W., Terella A., Schmidt E.V., Chung R.T. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol. 2002;76(17):8505–8517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC136407</ArticleId><ArticleId IdType="pubmed">12163570</ArticleId></ArticleIdList></Reference><Reference><Citation>El Kazzi P., Yaacoub C., Fajloun Z., Vanelle P., Decoly E., Coutard B., Barral K. 2C protein of Enterovirus: key protein of viral replication and antiviral target. Virologie. 2023;27(3):35–49. (Montrouge)</Citation><ArticleIdList><ArticleId IdType="pubmed">37476987</ArticleId></ArticleIdList></Reference><Reference><Citation>Keppeke G.D., Calise S.J., Chan E.K.L., Andrade L.E.C. Ribavirin induces widespread accumulation of IMP dehydrogenase into rods/rings structures in multiple major mouse organs. Antiviral Res. 2019;162:130–135.</Citation><ArticleIdList><ArticleId IdType="pubmed">30605724</ArticleId></ArticleIdList></Reference><Reference><Citation>Korboukh V.K., Lee C.A., Acevedo A., Vignuzzi M., Xiao Y., Arnold J.J., Hemperly S., Graci J.D., August A., Andino R., Cameron C.E. RNA virus population diversity, an optimum for maximal fitness and virulence. J. Biol. Chem. 2014;289(43):29531–29544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4207971</ArticleId><ArticleId IdType="pubmed">25213864</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B., Salzberg S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods. 2012;9(4):357–359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.M., Wu C.C., Wu S.E., Lin Y.H., Wang L.T., Chang C.R., Huang P.N., Shih S.R., Kuo R.L. The RNA-dependent RNA polymerase of enterovirus A71 associates with ribosomal proteins and positively regulates protein translation. RNA Biol. 2020;17(4):608–622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237135</ArticleId><ArticleId IdType="pubmed">32009553</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefkowitz E.J., Dempsey D.M., Hendrickson R.C., Orton R.J., Siddell S.G., Smith D.B. Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV) Nucleic Acids Res. 2018;46(D1):D708–D717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753373</ArticleId><ArticleId IdType="pubmed">29040670</ArticleId></ArticleIdList></Reference><Reference><Citation>Logotheti M., Pogka V., Horefti E., Papadakos K., Giannaki M., Pangalis A., Sgouras D., Mentis A. Laboratory investigation and phylogenetic analysis of enteroviruses involved in an aseptic meningitis outbreak in Greece during the summer of 2007. J. Clin. Virol. 2009;46(3):270–274.</Citation><ArticleIdList><ArticleId IdType="pubmed">19699142</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam A.J., Ferguson G., Stone D.M., Meredith J., Knowlson S., Auda G., Almond J.W., Minor P.D. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J. Virol. 2006;80(17):8653–8663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1563845</ArticleId><ArticleId IdType="pubmed">16912313</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattenberger F., Vila-Nistal M., Geller R. Increased RNA virus population diversity improves adaptability. Sci. Rep. 2021;11(1):6824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7994910</ArticleId><ArticleId IdType="pubmed">33767337</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T., Kwang J. Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice. J. Virol. 2014;88(10):5803–5815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019108</ArticleId><ArticleId IdType="pubmed">24623423</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor P.D. Live attenuated vaccines: historical successes and current challenges. Virology. 2015;479-480:379–392.</Citation><ArticleIdList><ArticleId IdType="pubmed">25864107</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinos-Quintana A., Perez-de Soto C., Gomez-Rosa M., Perez-Simon J.A., Perez-Hurtado J.M. Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients. Bone Marrow Transplant. 2013;48(2):265–268.</Citation><ArticleIdList><ArticleId IdType="pubmed">23000643</ArticleId></ArticleIdList></Reference><Reference><Citation>Park D.J., Dudas G., Wohl S., Goba A., Whitmer S.L., Andersen K.G., Sealfon R.S., Ladner J.T., Kugelman J.R., Matranga C.B., Winnicki S.M., Qu J., Gire S.K., Gladden-Young A., Jalloh S., Nosamiefan D., Yozwiak N.L., Moses L.M., Jiang P.P., Lin A.E., Schaffner S.F., Bird B., Towner J., Mamoh M., Gbakie M., Kanneh L., Kargbo D., Massally J.L., Kamara F.K., Konuwa E., Sellu J., Jalloh A.A., Mustapha I., Foday M., Yillah M., Erickson B.R., Sealy T., Blau D., Paddock C., Brault A., Amman B., Basile J., Bearden S., Belser J., Bergeron E., Campbell S., Chakrabarti A., Dodd K., Flint M., Gibbons A., Goodman C., Klena J., McMullan L., Morgan L., Russell B., Salzer J., Sanchez A., Wang D., Jungreis I., Tomkins-Tinch C., Kislyuk A., Lin M.F., Chapman S., MacInnis B., Matthews A., Bochicchio J., Hensley L.E., Kuhn J.H., Nusbaum C., Schieffelin J.S., Birren B.W., Forget M., Nichol S.T., Palacios G.F., Ndiaye D., Happi C., Gevao S.M., Vandi M.A., Kargbo B., Holmes E.C., Bedford T., Gnirke A., Stroher U., Rambaut A., Garry R.F., Sabeti P.C. Ebola virus epidemiology, transmission, and evolution during seven months in Sierra Leone. Cell. 2015;161(7):1516–1526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503805</ArticleId><ArticleId IdType="pubmed">26091036</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer J.K., Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc. Natl. Acad. Sci. U. S. A. 2003;100(12):7289–7294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165868</ArticleId><ArticleId IdType="pubmed">12754380</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiffer J.K., Kirkegaard K. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLOS Pathog. 2005;1(2):e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1250929</ArticleId><ArticleId IdType="pubmed">16220146</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt L.R., Estivariz C.F., Sutter R.W. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J. Infect. Dis. 2014;210:S380–S389. Suppl 1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10424844</ArticleId><ArticleId IdType="pubmed">25316859</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao C.D., Yergolkar P., Shankarappa K.S. Antigenic diversity of enteroviruses associated with nonpolio acute flaccid paralysis, India, 2007–2009. Emerg. Infect. Dis. 2012;18(11):1833–1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3559176</ArticleId><ArticleId IdType="pubmed">23092622</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter J., Koptides D., Tryfonos C., Christodoulou C. Molecular typing of enteroviruses associated with viral meningitis in Cyprus, 2000–2002. J. Med. Microbiol. 2006;55(Pt 8):1035–1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">16849723</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghipour S., Bek E.J., McMinn P.C. Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. J. Virol. 2013;87(3):1759–1769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554166</ArticleId><ArticleId IdType="pubmed">23175376</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghipour S., McMinn P.C. A study of the virulence in mice of high copying fidelity variants of human enterovirus 71. Virus Res. 2013;176(1–2):265–272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114468</ArticleId><ArticleId IdType="pubmed">23856384</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmonds P., Gorbalenya A.E., Harvala H., Hovi T., Knowles N.J., Lindberg A.M., Oberste M.S., Palmenberg A.C., Reuter G., Skern T., Tapparel C., Wolthers K.C., Woo P.C.Y., Zell R. Recommendations for the nomenclature of enteroviruses and rhinoviruses. Arch. Virol. 2020;165(3):793–797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7024059</ArticleId><ArticleId IdType="pubmed">31980941</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y., Zhang Y., Han Z., Xu W., Xiao J., Wang X., Wang J., Yang J., Yu Q., Yu D., Chen J., Huang W., Li J., Xie T., Lu H., Ji T., Yang Q., Yan D., Zhu S., Xu W. Genetic recombination in fast-spreading coxsackievirus A6 variants: a potential role in evolution and pathogenicity. Virus Evol. 2020;6(2):veaa048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8597624</ArticleId><ArticleId IdType="pubmed">34804589</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y., Zhang Y., Ji T., Gu X., Yang Q., Zhu S., Xu W., Xu Y., Shi Y., Huang X., Li Q., Deng H., Wang X., Yan D., Yu W., Wang S., Yu D., Xu W. Persistent circulation of coxsackievirus A6 of genotype D3 in mainland of China between 2008 and 2015. Sci. Rep. 2017;7(1):5491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5511160</ArticleId><ArticleId IdType="pubmed">28710474</ArticleId></ArticleIdList></Reference><Reference><Citation>VanBlargan L.A., Himansu S., Foreman B.M., Ebel G.D., Pierson T.C., Diamond M.S. An mRNA vaccine protects mice against multiple tick-transmitted Flavivirus infections. Cell Rep. 2018;25(12):3382–3392.e3383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6353567</ArticleId><ArticleId IdType="pubmed">30566864</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignuzzi M., Stone J.K., Andino R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res. 2005;107(2):173–181.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649563</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignuzzi M., Wendt E., Andino R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 2008;14(2):154–161.</Citation><ArticleIdList><ArticleId IdType="pubmed">18246077</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.H., Wang K., Zhao K., Hua S.C., Du J. The structure, function, and mechanisms of action of enterovirus non-structural protein 2C. Front. Microbiol. 2020;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7767853</ArticleId><ArticleId IdType="pubmed">33381104</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakovenko M.L., Korotkova E.A., Ivanova O.E., Eremeeva T.P., Samoilovich E., Uhova I., Gavrilin G.V., Agol V.I. Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance. J. Virol. 2009;83(7):3402–3406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2655595</ArticleId><ArticleId IdType="pubmed">19129444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Dong Z., Wei Q., Carr M.J., Li J., Ding S., Tong Y., Li D., Shi W. A neonatal murine model of coxsackievirus A6 infection for evaluation of antiviral and vaccine efficacy. J. Virol. 2017;91</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391469</ArticleId><ArticleId IdType="pubmed">28250116</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>